Leyden Labs a Dutch biotech has raised $70M in funding

Leyden Labs, a biotechnology company in the Netherlands, has recently received $70 million in funding to advance its intranasal antibody programs. The programs are intended to offer protection against a range of respiratory viruses, including influenza. The company is innovative in its approach, focusing on mucosal protection and preventing infections at their primary entry points.

Company Background

Leyden Labs was developed in 2020 with its primary focus towards developing broad spectrum antivirals. Based on the belief that immediate universal protection against those viruses currently as well as any that emerge hereafter should always be at hand in respiratory viruses. Targeting muco-epithelial cell tissues in the tracts of human respiratory, a product that ensures intercepting such viruses at an entry point.

Read also: AusperBio Therapeutics Completes $73 Million Series B

Funding Detail

The latest funding round of $70 million brings Leyden Labs’ total capital raised to about $270 million. This is after the successful $140 million Series B financing in 2021, led by Casdin Capital and GV (formerly Google Ventures), with participation from leading global life sciences investors.

Strategic Objectives

The funds acquired will be used for the following strategic initiatives:

• Development of intranasal antibody programs that expedite intranasal treatments, providing cross-protective immunity against viruses affecting the respiratory tract.
• Starting and expanding the scope of clinical trials to prove safety and efficacy of these intranasal drugs among different patients’ populations
• Ensuring liaison with regulatory agencies for compliance as well as a quicker approval cycle of new drug formulations.
• Manufacturing and Distribution: Scaling up the manufacturing operation along with distribution network in place to reach out across the world after regulatory approval.

New Approach to Respiratory Virus Protection

Leyden Labs’ intranasal antibody programs are a new approach to prevent respiratory infection. The intranasal delivery of antibodies directly targets and neutralizes the viruses in the mucosal surfaces of the respiratory tract at the point of entry. This could potentially have various benefits:

• Immediate Protection: Unlike vaccines, which take weeks to provoke an immune response, intranasal antibodies can provide immediate protection against viruses.
• Broad-Spectrum Efficacy: Potential to protect against multiple strains of viruses, including emerging variants that may evade vaccine-induced immunity.
• Non-Invasive Administration: Intranasal delivery is less invasive than injections, potentially improving patient compliance and acceptance.

Read also: Senseera a Israeli based biotech startup has raises $7.1M seed funding

Market Context

The COVID-19 pandemic has brought to light the urgent necessity for effective respiratory virus prevention strategies. Traditional vaccines and antiviral treatments have limitations, particularly concerning emerging variants and immediate protection needs. Leyden Labs’ approach addresses these challenges by offering a rapid and broad-spectrum protective solution.

Competitive Landscape

A larger interest has grown in the use of intranasal therapies of respiratory viruses as a new advancement in biotechnology. The use of intranasal vaccine candidates is also growing among other firms such as Altimmune and Meissa Vaccines, but this differentiates Leyden Labs in how it aims for a direct attack that will produce quick immunity with little to no antibodies from the human body’s responses.

Future Perspective

The significant investment would help Leyden Labs to intensify its efforts on research and development. This firm intends to begin clinical studies in order to demonstrate the safety and efficacy of their intranasal antibody treatments. In case such trials are successful, this will bring about a novel class of antiviral therapeutics that provides instant and extensive protection against respiratory viruses. Such medical therapy will address the important unmet need in the public health at a global scale.

Summary

Leyden Labs’ latest funding round of $70 million is a significant step toward the development of innovative solutions for respiratory virus protection. The company is advancing its intranasal antibody programs to provide immediate, broad-spectrum defense against influenza and other respiratory viruses. This approach has the potential to revolutionize the prevention and management of respiratory infections, contributing to improved global health outcomes.